Les inhibiteurs du facteur Xa = Factor Xa InhibitorsOLIVOT, Jean-Marc.Neurologie.com. 2010, Vol 2, Num 9-10, pp 262-264, issn 2100-9511, 3 p.Article

Stimulation of prothrombinase activity by the nonapeptide Thr-Trp-Ala-Arg-Asn-Ser-Tyr-Asn-Val, a segment of a plant thioninOSORIO E. CASTRO, Valdemar R; VERNON, Leo P.Peptides (New York, NY. 1980). 2003, Vol 24, Num 4, pp 515-521, issn 0196-9781, 7 p.Article

Test of the Month: The chromogenic antifactor Xa assayGEHRIE, Eric; LAPOSATA, Michael.American journal of hematology. 2012, Vol 87, Num 2, pp 194-196, issn 0361-8609, 3 p.Article

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasmaSAMAMA, Meyer Michel; AMIRAL, Jean; GUINET, Céline et al.Thrombosis and haemostasis. 2010, Vol 104, Num 5, pp 1078-1079, issn 0340-6245, 2 p.Article

Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test?TRIPODI, Armando.Thrombosis and haemostasis. 2011, Vol 105, Num 4, pp 735-736, issn 0340-6245, 2 p.Article

Factor Xa is a superior target to factor IIa for antithrombotic therapiesBÜLLER, Harry R.Seminars in thrombosis and hemostasis. 2003, Vol 29, issn 0094-6176, p. 37, SUP1Conference Paper

Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor XaGIARDINO, Edward C; HAERTLEIN, Barbara J; DE GARAVILLA, Lawrence et al.Blood coagulation & fibrinolysis. 2010, Vol 21, Num 2, pp 128-134, issn 0957-5235, 7 p.Article

Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clotsPRAGER, N. A; ABENDSCHEIN, D. R; MCKENZIE, C. R et al.Circulation (New York, N.Y.). 1995, Vol 92, Num 4, pp 962-967, issn 0009-7322Article

Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activationBORENSZTAJN, Keren; BIJLSMA, Maarten F; REITSMA, Pieter H et al.Thrombosis research. 2009, Vol 124, Num 2, pp 219-225, issn 0049-3848, 7 p.Article

Normal prothrombin time in the presence of therapeutic levels of rivaroxabanVEEN, Joost J. Van; SMITH, Julie; KITCHEN, Steve et al.British journal of haematology. 2013, Vol 160, Num 6, pp 859-860, issn 0007-1048, 2 p.Article

Functional characterisation of Vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoiLOURENCO OLIVEIRA, Daniella Gorete; ALVAREZ-FLORES, Miryam Paola; RIOS LOPES, Adriana et al.Thrombosis and haemostasis. 2012, Vol 108, Num 3, pp 570-578, issn 0340-6245, 9 p.Article

Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agentsFUKUDA, Toshio; HONDA, Yuko; KAMISATO, Chikako et al.Thrombosis and haemostasis. 2012, Vol 107, Num 2, pp 253-259, issn 0340-6245, 7 p.Article

The contribution of anti-Xa and anti-lla activities to the profibrinolytic activity of low-molecular-weight heparinsAMMOLLO, Concetta T; SEMERARO, Fabrizio; SEMERARO, Nicola et al.Thrombosis and haemostasis. 2009, Vol 101, Num 4, pp 782-785, issn 0340-6245, 4 p.Article

Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitorPACCALY, Anne; OZOUX, Marie-Laure; CHU, Valeria et al.Thrombosis and haemostasis. 2005, Vol 94, Num 6, pp 1156-1163, issn 0340-6245, 8 p.Article

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 : an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjectsKUHITZA, Dagmar; BECKA, Michael; WENSING, Georg et al.European journal of clinical pharmacology. 2005, Vol 61, Num 12, pp 873-880, issn 0031-6970, 8 p.Article

Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptideHAGEMEYER, Christoph E; TOMIC, Ivo; JAMINET, Patrick et al.Thrombosis and haemostasis. 2004, Vol 92, Num 1, pp 47-53, issn 0340-6245, 7 p.Article

Is the monitoring of anti-Xa activity necessary in pregnant women undergoing thromboprophylaxis?O'CONNELL, Michael P; O'LEARY, Michael; MACKEOGH, Luke et al.European journal of obstetrics, gynecology, and reproductive biology. 2004, Vol 114, Num 1, pp 12-14, issn 0301-2115, 3 p.Article

Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a: A direct and selective antagonist : Pharmacotherapy in cardiovascular diseases and vascular interventionsBECKER, Richard C; ALEXANDER, John; YOU FU LI et al.Thrombosis and haemostasis. 2004, Vol 92, Num 6, pp 1229-1231, issn 0340-6245, 3 p.Article

Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease : Pharmacotherapy in cardiovascular diseases and vascular interventionsBECKER, Richard C; ALEXANDER, John; DYKE, Christopher K et al.Thrombosis and haemostasis. 2004, Vol 92, Num 6, pp 1182-1193, issn 0340-6245, 12 p.Article

Limitations of the laboratory monitoring of heparin therapyGREAVES, Mike.Thrombosis and haemostasis. 2002, Vol 87, Num 1, pp 163-164, issn 0340-6245Article

Effects of calcium ions on the interactions between antithrombin and factor Xa mediated by variously sulfated, semisynthetic low-molecular-weight heparinsSISSI, Claudia; LUCATELLO, Lorena; NAGGI, Annamaria et al.Seminars in thrombosis and hemostasis. 2002, Vol 28, Num 4, pp 355-359, issn 0094-6176Article

Fondaparinux sodium: A selective inhibitor of factor XaBAUER, Kenneth A.American journal of health-system pharmacy. 2001, Vol 58, Num 21, pp S14-S17, issn 1079-2082, SUP2Article

In vitro characterization of a novel factor Xa inhibitor, RPR 130737CHU, V; BROWN, K; COLUSSI, D et al.Thrombosis research. 2000, Vol 99, Num 1, pp 71-82, issn 0049-3848Article

A new factor Xa inhibitor (Lefaxin) from the Haementeria depressa leechFARIA, F; KELEN, E. M. A; SAMPAIO, C. A. M et al.Thrombosis and haemostasis. 1999, Vol 82, Num 5, pp 1469-1473, issn 0340-6245Article

Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assayHARENBERG, J; HAAF, B; DEMPFLE, C. E et al.Nephrology, dialysis, transplantation (Print). 1995, Vol 10, Num 2, pp 217-222, issn 0931-0509Article